06/02/23 10:15 AMNasdaq : GNPX clinical trialGenprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical TrialAUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is workingRHEA-AIvery positive
05/30/23 7:30 AMNasdaq : GNPX clinical trialGenprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung CancerGenprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 portion of the Acclaim-1...RHEA-AIneutral
05/25/23 5:00 PMNasdaq : GNPX clinical trialGenprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual MeetingGenprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...RHEA-AIneutral
05/23/23 7:30 AMNasdaq : GNPX clinical trialGenprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery SystemGenprex, Inc., a clinical-stage gene therapy company...RHEA-AIneutral
05/08/23 7:30 AMNasdaq : GNPX conferencesGenprex to Participate and Present at Upcoming May Industry and Investor ConferencesGenprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming industry and investor...RHEA-AIneutral
04/19/23 9:11 AMNasdaq : GNPX clinical trialGenprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual MeetingGenprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for the NPRL2 gene. "We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery...RHEA-AIvery positive
04/18/23 9:11 AMNasdaq : GNPX Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for GlioblastomaPre-clinical Study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivoStudy adds to the growing body of research examining TUSC2 as a target for multiple other cancersTUSC2 is the tumor suppressorRHEA-AIneutral
03/23/23 7:30 AMNasdaq : GNPX Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene TherapiesRodney Varner, CEO of Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today commended The U.S. Food and Drug Administration's initiative that aims to expedite the development of gene therapies for patients with rare diseases. "The FDA's efforts to streamline the...RHEA-AIneutral
03/13/23 7:30 AMNasdaq : GNPX conferencesGenprex to Present at Bioprocessing Summit ConferenceGenprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona,...RHEA-AIneutral
03/08/23 7:30 AMNasdaq : GNPX conferencesGenprex to Participate in March Investor and Industry ConferencesGenprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in March 2023. In attendance at the Roth Conference will be Genprex's Chief Financial Officer, Ryan...RHEA-AIneutral